TNP-470
TNP-470 is a synthetic analog of fumagillin, a natural product derived from the fungus Aspergillus fumigatus. It is primarily known for its anti-angiogenic properties, which means it can inhibit the formation of new blood vessels. This characteristic makes TNP-470 a potential therapeutic agent in the treatment of various diseases, including cancer and age-related macular degeneration.
Mechanism of Action[edit]
TNP-470 exerts its effects by inhibiting methionine aminopeptidase 2 (MetAP2), an enzyme that plays a crucial role in the process of angiogenesis. By blocking MetAP2, TNP-470 prevents the proliferation and migration of endothelial cells, which are essential for the formation of new blood vessels. This inhibition can starve tumors of the necessary blood supply, thereby inhibiting their growth and metastasis.
Clinical Applications[edit]
TNP-470 has been investigated in various clinical trials for its potential use in treating different types of cancer, including breast cancer, prostate cancer, and glioblastoma. It has also been studied for its effects on non-cancerous conditions that involve abnormal blood vessel growth, such as diabetic retinopathy and psoriasis.
Cancer Treatment[edit]
In cancer therapy, TNP-470 is often used in combination with other treatments such as chemotherapy and radiation therapy. Its ability to inhibit angiogenesis can enhance the effectiveness of these treatments by reducing the tumor's ability to repair and grow.
Ophthalmology[edit]
TNP-470 has shown promise in the treatment of age-related macular degeneration (AMD) and other eye diseases characterized by abnormal blood vessel growth. By inhibiting angiogenesis, TNP-470 can potentially slow the progression of these diseases and preserve vision.
Side Effects[edit]
While TNP-470 has shown potential in various therapeutic areas, it is not without side effects. Common adverse effects include neurotoxicity, which can manifest as dizziness, confusion, and peripheral neuropathy. These side effects have limited the widespread use of TNP-470 and have led researchers to explore derivatives and alternative formulations that might reduce toxicity.
Related Pages[edit]
- Angiogenesis
- Cancer
- Chemotherapy
- Radiation therapy
- Age-related macular degeneration
- Diabetic retinopathy
- Psoriasis
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
